Combination immunotherapy for the treatment of cancer
Agonists to ICOS in combination with a blocking agent to a T cell inhibitory receptor (e.g., CTLA-4, PD-1, etc.) are demonstrated herein to be useful for the treatment of tumors.
1. A method of treating cancer in a patient comprising administering to the patient simultaneously or sequentially a blocking anti-PD-1 antibody and an ICOS ligand (ICOS-L).
2. The method of claim 1 , wherein the ICOS ligand is soluble.
3. The method of claim 1 , wherein the ICOS ligand is expressed on the surface of a cell.
4. The method of claim 3 , wherein the cell is a tumor cell.
5. The method of claim 4 , wherein the tumor cell is irradiated.
6. The method of claim 4 , wherein the tumor cell was surgically removed from the patient.
7. The method of claim 1 consisting of administering to the patient, simultaneously or sequentially, one or more doses of a blocking anti-PD-1 antibody and one or more doses of an ICOS ligand (ICOS-L).
8. The method of claim 1 , wherein the method does not comprise administering another antitumor treatment.
9. The method of claim 1 , wherein the method does not comprise administering another antitumor treatment other than surgical resection or radiation therapy.
10. The method of claim 1 , wherein the method does not comprise administering another immunotherapy.